Interventions for valvular disease and heart failure

In-hospital and thirty-day outcomes of the SAPIEN 3 Ultra balloon-expandable transcatheter aortic valve: the S3U registry

EuroIntervention 2020;15:1240-1247. DOI: 10.4244/EIJ-D-19-00541

Francesco Saia
Francesco Saia1, MD, PhD; Caterina Gandolfo2, MD; Tullio Palmerini1, MD; Sergio Berti3, MD; Sagar N. Doshi4, MD; Mika Laine5, MD; Chiara Marcelli1, MD; Tommaso Piva6, MD; Flavio Ribichini7, MD; Mauro De Benedictis8, MD; Francesco Cardaioli9, MD; Stefano Cannata2, MD; Giuseppe Tarantini9, MD, PhD
1. Cardiology unit, Cardio-Thoracic-Vascular Department, University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy; 2. Interventional Cardiology, IRCSS-ISMETT-University of Pittsburgh Medical Center (UPMC), Palermo, Italy; 3. U.O.C Cardiologia Diagnostica ed Interventistica, Fondazione C.N.R. Reg. Toscana G Monasterio, Massa, Italy; 4. Cardiology Dept – Queen Elizabeth University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 5. Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland; 6. Interventional Cardiology, Ospedali Riuniti di Ancona, Ancona, Italy; 7. Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy; 8. Department of Cardiology, Mauriziano Hospital, Turin, Italy; 9. Interventional Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

Aims: The aim of this study was to evaluate 30-day safety and efficacy outcomes of transcatheter aortic valve implantation (TAVI) performed with the SAPIEN 3 Ultra system.

Methods and results: The S3U registry is a physician-led, post-approval, multicentre, observational registry of transfemoral TAVI with the SAPIEN 3 Ultra. New features include an improved sealing skirt, a 14 Fr expandable sheath and a new delivery catheter. Overall, 139 consecutive patients at nine participating centres were enrolled. Mean age was 81.4±8.3 years, average STS score 3.8±2.4%. The vast majority (97.2%) underwent TAVI with local anaesthesia (28.8%) or conscious sedation (68.3%). Balloon predilatation was performed in 30 patients (21.6%), post-dilatation in three (2.2%). In-hospital, there were no cases of death, stroke, or conversion to open heart surgery. Major vascular complications occurred in three patients (2.2%), as well as major or life-threatening bleedings in three patients (2.2%). There were two moderate (1.4%) and no moderate/severe paravalvular leaks. Median length of stay after TAVI was three days (IQR 3-5 days). At 30 days, there were no deaths, MI, or strokes, and the incidence of new permanent pacemaker implantation was 4.4%.

Conclusions: This first multicentre international experience of transfemoral TAVI with the SAPIEN 3 Ultra transcatheter heart valve shows good in-hospital and 30-day clinical outcomes.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

aortic stenosisfemoralmiscellaneoustavi
Interventions for valvular diseaseTAVI
Read next article
Transcatheter mitral valve repair in patients with acute myocardial infarction: insights from the European Registry of MitraClip in Acute Mitral Regurgitation following an acute myocardial infarction (EREMMI)

Latest news